Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ... recent debate among weed scientists about how -- or even whether -- invasive saltcedar should ... answer critical questions about our natural ecosystems and carefully weigh the impact of our decisions. ... Lawrence, KS (PRWEB) August ...
... HANOVER, NH Despite their popularity in the science fiction ... the mysterious regions in space once thought to be absent ... issue of Physical Review Letters , the flagship journal ... way of creating a reproduction black hole in the laboratory ...
... , NANJING, China, Aug. 21 ... ("Simcere" or the "Company"), a leading manufacturer and supplier,of ... forty-two of its generic drugs have been included in ... Ministry of Health ("MOH") on,August 18, 2009. , ...
Cached Biology Technology:Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 2Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 3Dartmouth researchers propose new way to reproduce a black hole 2Forty-two of Simcere's Generic Drugs Enter China's Essential Drug List 2
(Date:4/17/2014)... in German . ... they also provide us with a continuous stream of information ... or sit still in a car the world glides ... retinas. Seemingly without effort, our brain calculates self-motion from this ... and a steady gaze during our own movements. Together with ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... Oak Ridge National Laboratory have received seven R&D 100 Awards ... to as the "Academy Awards of Science," honor the 100 ... chosen by an expert panel of independent judges and the ... year,s R&D 100 award winners," Energy Secretary Steven Chu said. ...
... to increased awareness generated by the expanding local ... throughout the United States. The fresh market strawberry ... Floridastates with ideal weather conditions and long growing ... production operations succeed in other areas of the ...
... (CHICAGO) A neurological scientist at Rush University Medical ... of Health (NIH) to evaluate whether cinnamon, a common ... process of multiple sclerosis (MS). The two-year, $750,000 ... effects of cinnamon on the disease process in mice. ...
Cached Biology News:ORNL researchers win 7 R&D 100 awards 2ORNL researchers win 7 R&D 100 awards 3ORNL researchers win 7 R&D 100 awards 4ORNL researchers win 7 R&D 100 awards 5Early-season strawberry tested in high elevation conditions 2Potential impact of cinnamon on multiple sclerosis studied 2Potential impact of cinnamon on multiple sclerosis studied 3
... is Tecans fully automated solution for ... fast automation for cell-line maintenance, expansion, ... modular system built upon standard, industry ... liquid handling configuration capable of both ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
... ) The antibody is preadsorbed to remove any ... buffered aqueous glycerol solution A solution ... 2+ and Ca 2+ ), pH 7.3 ... (IgG, protease free) and 0.05% sodium azide A ...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
Biology Products: